6.3 Antiepileptic Drug (AED) Pharmacology & Monitoring

Antiepileptic Drug (AED) Pharmacology & Monitoring

Fundamental Principles of AED Pharmacokinetics

The management of epilepsy relies heavily on the chronic administration of Antiepileptic Drugs (AEDs). A deep understanding of AED pharmacokinetics (absorption, distribution, metabolism, and excretion) is essential for optimizing seizure control while minimizing toxicity. The therapeutic window for many AEDs is narrow, necessitating precise dosing and diligent clinical and laboratory monitoring.

Several factors complicate AED pharmacology. First, many older generation AEDs are highly protein-bound, primarily to serum albumin. For example, phenytoin is approximately 90% protein-bound. Only the unbound, or "free," fraction of the drug is pharmacologically active and capable of crossing the blood-brain barrier to exert its effect. In conditions that lower serum albumin (e.g., malnutrition, severe liver disease, renal failure, critical illness, or pregnancy), the total drug concentration may appear falsely low or normal, while the free fraction is actually in the toxic range. Therefore, checking free phenytoin levels is critical in these populations.

Second, AEDs frequently participate in complex drug-drug interactions, primarily mediated through the hepatic cytochrome P450 (CYP450) enzyme system. Some AEDs are potent enzyme inducers, accelerating the metabolism of other drugs (including other AEDs, oral contraceptives, and anticoagulants), leading to decreased efficacy. Classic enzyme inducers include phenytoin, carbamazepine, and phenobarbital. Conversely, some AEDs, most notably valproic acid, are potent enzyme inhibitors, which can significantly increase the plasma concentrations of co-administered medications, precipitating toxicity.

Zero-Order Kinetics: The Phenytoin Paradigm

Phenytoin exhibits a unique pharmacokinetic profile characterized by Michaelis-Menten, or non-linear, zero-order kinetics at therapeutic concentrations. Most medications follow first-order kinetics, meaning a constant percentage of the drug is eliminated per unit of time; as the dose increases, the plasma concentration increases proportionally and linearly.

In contrast, zero-order kinetics means a constant amount of the drug is eliminated per unit of time, regardless of the plasma concentration. This occurs because the hepatic enzymes responsible for metabolizing phenytoin (CYP2C9 and CYP2C19) become saturated within the standard therapeutic dosing range. Once saturation is reached, any small increase in the phenytoin dose will lead to a disproportionately large, non-linear increase in the serum concentration, rapidly pushing the patient from a therapeutic level into profound toxicity.

Clinically, this implies that dosage adjustments for phenytoin must be made very cautiously, often in tiny increments (e.g., 25-50 mg), once the serum level is near the target range. Phenytoin toxicity manifests initially with horizontal nystagmus, progressing to ataxia, slurred speech, lethargy, confusion, and paradoxically, an increase in seizure frequency at extremely high levels. Long-term adverse effects include gingival hyperplasia, hirsutism, osteomalacia, and peripheral neuropathy.

Pharmacogenomics and HLA-B*1502 Screening

Adverse cutaneous drug reactions are a significant concern with several AEDs, particularly the aromatic anticonvulsants: carbamazepine, oxcarbazepine, phenytoin, phenobarbital, and lamotrigine. These reactions range from benign maculopapular rashes to life-threatening emergencies, namely Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

A major breakthrough in personalized epilepsy care is the identification of genetic markers that strongly predict the risk of these severe reactions. The human leukocyte antigen (HLA) allele HLA-B*1502 is highly associated with a dramatically increased risk of developing SJS/TEN when exposed to carbamazepine (and to a lesser extent, oxcarbazepine and phenytoin).

The HLA-B*1502 allele is most prevalent in specific populations of Asian descent, particularly Han Chinese, Filipinos, Malaysians, and Thai populations, where the allele frequency can be up to 10-15%. In contrast, it is extremely rare in Caucasian, African, and Hispanic populations.

The FDA requires mandatory screening for the HLA-B1502 allele in patients of Asian ancestry prior to initiating therapy with carbamazepine. If a patient tests positive for the allele, carbamazepine should not be prescribed unless the expected benefit clearly outweighs the risk, and alternative agents must be heavily prioritized. This pharmacogenomic screening has drastically reduced the incidence of carbamazepine-induced SJS/TEN in at-risk populations. Another allele, HLA-A3101, is associated with a broader range of hypersensitivity reactions to carbamazepine (including maculopapular rash, DRESS syndrome, and SJS/TEN) and is seen more commonly in Japanese, Korean, and European populations, though screening is currently recommended but not uniformly mandated.

Therapeutic Drug Monitoring (TDM)

Therapeutic drug monitoring involves measuring the concentration of a drug in the blood to optimize dosing. While traditional AEDs (phenytoin, carbamazepine, valproic acid, phenobarbital) have well-established "therapeutic ranges," modern practice emphasizes the "individual therapeutic concentration." This is the concentration at which an individual patient achieves optimal seizure control without intolerable side effects, which may fall outside the standard reference range.

TDM is essential in several clinical scenarios:

1. Establishing a baseline: After a patient achieves seizure freedom, obtaining a level provides a target for future reference.
2. Suspected non-adherence: A common cause of breakthrough seizures.
3. Suspected toxicity: When clinical signs suggest drug overload.
4. Physiological changes: Pregnancy, significant weight changes, or critical illness alter pharmacokinetics.
5. Drug interactions: When adding or removing medications known to induce or inhibit metabolism.
6. Formulation changes: When switching between brand and generic formulations or different delivery mechanisms (e.g., immediate to extended-release).